/
Information Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies.
Operating margin is thin at 4.00%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 16.5% YoY with margins expanding 2.1pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$292M
▲ +16.5% YoY
Net Income (TTM)
$21M
▲ +59.4% YoY
Op. Margin
5.40%
▲ +2.1pp YoY
ROIC
2.88%
▲ +1.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$47M
▲ +525.9% YoY
Op. Cash Flow (TTM)
$62M
▼ -10.8% YoY
Net Debt
-$50M
Net Cash Position
Cash & Equiv.
$145M
5Y CAGR: +17.3%
5Y CAGR: +10.6%
Continue Research